Diligence memo · auto-generated · as of July 2, 2026
Pionyr Immunotherapeutics, Inc.
Pionyr Immunotherapeutics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Pionyr Immunotherapeutics, Inc. operates in Other Health Care, based in SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pionyr Immunotherapeutics, Inc. has raised $45M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $38M on 2017-12-07.
Most recent recorded round closed around 2018-03-27.
Valuation (modeled)modeled
Provath models Pionyr Immunotherapeutics, Inc. at approximately $155M (range $16M–$597M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.35× the median modeled value of Series B Other Health Care companies in 2016–2018 (74 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 4 months.
Last raise 8.3 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 5.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 91% of Other Health Care peers (5377 compared).
Modeled value ranks above 85% of those peers.
Closest niche peers: Podicare Services, Inc., COTA, Inc., Fresenius Medical Care - Meridian Health System, LLC, Headspace, Inc., Spine Holdings LLC.
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.